Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
Top Cited Papers
Open Access
- 10 July 2012
- journal article
- research article
- Published by Wiley in Angewandte Chemie
- Vol. 51 (34), 8529-8533
- https://doi.org/10.1002/anie.201203263
Abstract
Special (lipid) delivery: The role of the ionizable lipid pKa in the in vivo delivery of siRNA by lipid nanoparticles has been studied with a large number of head group modifications to the lipids. A tight correlation between the lipid pKa value and silencing of the mouse FVII gene (FVII ED50) was found, with an optimal pKa range of 6.2–6.5 (see graph). The most potent cationic lipid from this study has ED50 levels around 0.005 mg kg−1 in mice and less than 0.03 mg kg−1 in non‐human primates.Keywords
This publication has 16 references indexed in Scilit:
- Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based MechanismsMolecular Therapy, 2010
- Development of Lipidoid–siRNA Formulations for Systemic Delivery to the LiverMolecular Therapy, 2009
- Knocking down barriers: advances in siRNA deliveryNature Reviews Drug Discovery, 2009
- Nonviral delivery of synthetic siRNAs in vivoJCI Insight, 2007
- Interfering with disease: a progress report on siRNA-based therapeuticsNature Reviews Drug Discovery, 2007
- Selective silencing of a mutant transthyretin allele by small interfering RNAsBiochemical and Biophysical Research Communications, 2005
- Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acidsJournal of Controlled Release, 2005
- The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouseBiochemical and Biophysical Research Communications, 2005
- On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acidsGene Therapy, 2001
- Modulation of Membrane Fusion by Asymmetric Transbilayer Distributions of Amino LipidsBiochemistry, 1994